NIFTY 50

Biocon receives DCGI nod for use of Itolizumab drug in moderate to severe COVID-19 patients

Updated : July 13, 2020 04:52 PM IST

Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications,
Itolizumab is now approved for the treatment of CRS in patients with moderate to severe ARDS due to COVID-19.

You May Also Like

Live TV

recommended for you